Coronary Artery Disease, Diabetes Mellitus, Type 2, Dyslipidemias, Metabolic Syndrome, Obesity
Conditions
Brief summary
Systematic metabolic diseases are closely related to prevalence and progression of atherosclerosis. This prospective cohort consecutively enrolls patients with coronary artery disease compliacted with metabolic abnormalities such as diabtetes, prediabetes, obesity, chronic kidney disease and hyperuricemia.
Detailed description
CArdioMetabolism and Atherosclerotic PlaqUe progreSsion (CAMPUS) study is a single center, prospective cohort study to investigate the impact of cardiometabolic factors on coronary diseases. This study consecutively enrolls patients with coronary artery diseases complicatied with metabolic abnormalities, including diabetes, prediabetes, obesity, chronic kidney disease and hyperuricemia.
Interventions
None listed
Sponsors
Ruijin Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Age 18-80 years * Established coronary artery disease or metabolic disorders, including: 1. Type 2 diabetes diagnosed by one of the following criteria: HbA1c \>/= 6.5% Fasting plasma glucose \>/= 7.0 mmol/l (confirmed) 2h plasma glucose value during OGTT \>/= 11.1 mmol/l Already receiving glucose-lowering agents 2. Prediabetes 3. Obesity 4. Chronic kidney disease 5. Hyperuricemia 6. Dyslipidemia
Exclusion criteria
* Severe liver failure (Child-Pugh grade B to C) * Severe anemia (hemoglobin \< 60g/L) * Familial hypercholesterolemia * Active malignant tumor * Active autoimmune diseases on corticosteroids * Acute or chronic infection * Life expectancy \< 1 year
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Coronary plaque progression | 12 months | Assessed by coronary angiography and QCA |
| Coronary lesion severity | 12 months | Assessed by coronary angiography and QCA |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Coronary plaque characteristics | 12 months | Assessed by intravascular imaging (IVUS or OCT) |
| Cardiovascular events | up to 5 years | The incidence of MACCE (major adverse cardio and cerebral vascular events), lesion associated events (target lesion myocardial infarction, target lesion faliure, target vessel revascularization, etc.) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Glycated modifications of lipoproteins | up to 2 years | Glycated modifications of lipoproteins in patients, such as ApoA-I glycation. |
| Lipoprotein function assessment | up to 2 years | HDL functions, including reverse cholesterol transport assessed by cholesterol efflux capacity, anti-inflammatory function, and anti-oxidation function |
| Diabetic complications | up to 5 years | Prevalence of diabetic complications, including peripheral artery disease, retinopathy, nephropathy, encephalopathy. |
Countries
China
Contacts
Primary ContactXiaoqun Wang, M.D., Ph.D.
Backup ContactShuo Feng, M.D.
Outcome results
None listed